Alcon Highlights Upcoming Activities During the 14th Annual EURETINA Congress, to be Held September 11-14
Sep 04, 2014
New data to highlight safety profile and efficacy of JETREA®(ocriplasmin) in real-world clinical practice
Product introductions include the FINESSE™ Flex Loop and additions to its ULTRAVIT® High Speed Vitrectomy Probes with new 27+® fine-gauge instrumentation
LONDON, September 8, 2014 – Alcon, the global leader in eye care and a division of Novartis, announces its upcoming presentations, launches and events to take place during the 14th Annual EURETINA Congress in London, starting on September 11.
Retina-related Data Presentations Among the presentation highlights will be efficacy and safety data for JETREA® (ocriplasmin) based on real-world clinical experience. Two presentations will feature data from single-center studies and one study will provide an evaluation of real-world safety data collected from regulatory authorities around the world. In addition, two new analyses will report on vision-related quality-of-life for patients following treatment with JETREA®, as well as details on the safety profile of the product.
Ocriplasmin in the Clinical Setting: An Overview of Post-approval Safety Outcomes (Free Paper Session 1; Oral; September 11, 2014; 8:00-10:00 GMT, Auditorium)
The Time-Course and Resolution of Key Adverse Events in the Ocriplasmin Clinical Trial Programme (Free Paper Session 11; Oral; September 13, 2014; 11:00-13:00 GMT, Boulevard E)
Clinical Experience with Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: A Single-Centre Case Series (Free Paper Session 11; September 13, 2014; 11:00-13:00 GMT, Auditorium)
Improved Vision-Related Functionality in Patients with Symptomatic Vitreomacular Adhesion, after Intravitreal Ocriplasmin Injection - Analyses from TG-MV-006 and TG-MV-007 (E-Poster Session)
A Single-Centre Study with Ocriplasmin in Homogenous Group of Patients with Vitreomacular Traction (E-Poster Session)
The Impact of Valved and Non-Valved Cannula on Intraoperative Fluid Dynamics and Vitreous (E-Poster Session)
Surgical Vitreoretinal Product Launches Alcon has expanded its line of ULTRAVIT® High Speed Vitrectomy Probes with new 27+® fine-gauge instrumentation. In addition, Alcon will introduce the newest member of its Grieshaber® instrumentation portfolio, the FINESSE™ Flex Loop.
Additional Alcon-related Events As the global leader in eye care, Alcon has a number of educational events planned during the 14th Annual EURETINA Congress that are open to attendees; however, please note that registration may be required to attend:
Friday, Sept. 12
Faster and Smaller in Retina Surgery: A Video Presentation of New Technologies and Techniques: 10:00-11:00, ExCel, Boulevard C
Saturday, Sept. 13
Novartis/Alcon Retina Race: 06:30, Western Gateway Royal Victoria Dock
Live Surgery: Advancements in Techniques andTechnologies: 18:15-20:00, ExCeL, Auditorium
Sunday, Sept. 14
Enhancing Surgeon Confidence and Patient Outcomes Leveraging Minimally Invasive Cataract Surgery: 13:00-14:00, ExCel, Boulevard B
Precision Dry Eye Care in Refractive Surgery: 13:00-14:00, ExCeL, Capital Hall A
Optimise your Cataract and Refractive Workflow with Alcon Technology: 18:15-19:15, ExCeL, Boulevard F
Monday, Sept. 15
360o Overview on Astigmatism Surgical Management: 3D Alcon Visionarium: 13:00-14:00, ExCeL, Capital Hall B
Cataract Surgery Outcomes Optimization with Innovative Drugs andTechnologies: 13:00-14:00, ExCel, Boulevard F
For More Information Healthcare professionals attending EURETINA will also be able to visit the Novartis and Alcon booth (Booth #B10). Additional information about Alcon activities, as well as data news announced at EURETINA, can be found at www.novartisalconretina.com.
About Alcon Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Alcon’s three businesses – Surgical, Pharmaceutical, and Vision Care – offer the widest spectrum of eye care products in the world. Alcon is the second largest division of the Novartis Group, with net sales of USD 10.5 billion in 2013. Headquartered in Fort Worth, Texas, USA, Alcon has more than 25,000 employees worldwide, operations in 75 countries and products available in 180 markets. For more information, visit www.alcon.com.
Elizabeth Harness Murphy Alcon Global Communications +1 817 551 8696 (direct) +1 585 435 7379 (mobile) [email protected]